TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Stud
What's Going On With TransCode Therapeutics Stock Wednesday? - TransCode Therapeutics (NASDAQ:RNAZ), CK Life Sciences Intl (OTC:CKLSF)